Skip to main content

Nina Paulshus Sundlisæter

Postdok
https://orcid.org/0000-0002-1295-0172
Se Google Scholar profil
Se publikasjoner i PubMed

Utdanning

  • Cand.med ved Universitet i Bergen
  • Spesialist i revmatologi
  • Doktorgrad (PhD) ved Institutt for klinisk medisin, Universitetet i Oslo

Stilling

  • Overlege ved Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet sykehus
  • Post doc, Klinikk for revmatologi, poliklinikk og forskning, Diakonhjemmet Sykehus

Interessefelt

  • Revmatologi
  • Utfallsmål
  • Prediksjon
  • Oppfølging og behandling
  • Randomiserte kontrollerte studier

E-post

Telefon

+47 22451500

Besøksadresse

Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postadresse

Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo

Prosjekter

WP1 - Behandlingsstudier

ARCTIC

Remisjon hos pasienter med revmatoid artritt: en randomisert kontrollert studie som undersøker bruk av ultralyd i klinisk oppfølging

WP1 - Behandlingsstudier

ARCTIC REWIND

Studie på nedtrapping av behandling ved revmatoid artritt uten tap av sykdomskontroll.

WP1 - Behandlingsstudier

ARCTIC REWIND extension study

Langtidsoppfølging av pasienter med velkontrollert revmatoid artritt - ARCTIC REWIND forlengelsesstudien

WP5 - Strategier for digital oppfølging

NOR-Flare

Avstandsoppfølging av pasienter med revmatoid artritt

WP2 - Presisjonsmedisin

START

Tidlig diagnose ved nylig oppstått leddbetennelse

Publikasjoner

Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):

Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis

2026

Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial

2025

Development of machine learning models for predicting non-remission in early RA highlights the robust predictive importance of the RAID score-evidence from the ARCTIC study

2025

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial

2024

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

2024

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

2024

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

2023

Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis and Excellent Disease Control

2023

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

2022

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

2022

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

2021

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients with Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-To-Target strategy

2021

Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol

2018

Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: Associations to future good radiographic and physical outcomes

2018

Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis

2017